Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Cash from Operations (2016 - 2026)

Relmada Therapeutics has reported Cash from Operations over the past 3 years, most recently at 3540.0 for Q1 2014.

  • Quarterly Cash from Operations fell 20.33% to 3540.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was 20646.0 through Feb 2014, down 204.74% year-over-year, with the annual reading at 45786988.0 for FY2025, 11.53% up from the prior year.
  • Cash from Operations was 3540.0 for Q1 2014 at Relmada Therapeutics, up from 9124.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 1497.0 in Q4 2012 and troughed at 9124.0 in Q4 2013.
  • The 3-year median for Cash from Operations is 3344.0 (2012), against an average of 3497.0.
  • Year-over-year, Cash from Operations plummeted 709.49% in 2013 and then dropped 20.33% in 2014.
  • A 3-year view of Cash from Operations shows it stood at 1497.0 in 2012, then crashed by 709.49% to 9124.0 in 2013, then skyrocketed by 61.2% to 3540.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Cash from Operations are 3540.0 (Q1 2014), 9124.0 (Q4 2013), and 5040.0 (Q2 2013).